Skip To Main Content
Karen Langhauser on Muck Rack

Karen Langhauser

Verified
(She/Her)
New Jersey
As seen in: Cell & Gene Therapy Review, CompareNetworks, LinkedIn, s-ge.com, Justmeans, Control Global, Pharma Manufacturing, Plant Services, Chemical Processing, Tablets & Capsules Magazine
Covers:  late stage development, scale up and manufacturing of drugs, as well as business challenges in the pharma industry
Doesn't Cover: medical devices, health care
Retired roller derby queen, reporting on pharma for @TabletsCapsules and @CgtReview - Occasionally funny, sometimes even on purpose. All opinions are my own.

Get in touch with Karen

Contact Karen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Karen Langhauser’s Biography

Read Full Bio →

Karen currently serves as Pharma Manufacturing's chief content director.

Now having dedicated her entire career to b2b journalism, Karen got her start writing for Food Manufacturing magazine. She made the decision to trade food for drugs in 2013, when she joined Putman Media as the digital content manager for Pharma Manufacturing, later taking the helm on the brand in 2016.

As an award-winning journalist with 20+ years experience writing in the manufacturing space, Karen passionately believes t…

Karen Langhauser’s Journalist Portfolio

Nevertheless, they persisted

Nevertheless, they persisted

How drugmakers are fighting to keep reproductive health drugs available, safe and legal

View article →
Pharma's weight loss challenge: The incretin effect

Pharma's weight loss challenge: The incretin effect

This three-part series will dig into incretin mimetics, their rise to fame in weight management and what it w…

View article →

Articles

RNA's comeback tour

|
By Karen Langhauser Verified
| Cell & Gene Therapy Review Verified
For decades, scientists dreamed about the seemingly limitless therapeutic potential of RNA. Part of what made RNA so compelling was its versatility. Across its various forms, RNA could target previously undruggable disease drivers, instruct cells to produce therapeutic proteins, silence harmful mutations, rewrite faulty RNA transcripts before they were translated into dysfunctional proteins, or train the immune system to fight disease.
Open in Who Shared Issue with article?

Oral Solid Dose Regulatory Approval Update

|
By Karen Langhauser Verified
| Tablets & Capsules Magazine Verified
With seven months of 2026 behind us, here’s a look at the regulatory wins shaping the U.S. oral solid dose sector. Last year, the Center for Drug Evaluation and Research (CDER) approved a total of 46 new drugs, 43% of which were OSD formulations — 14 tablets, four capsules, one tablet/capsule co-pack, and one approval in both capsule and tablet form. How is 2026 shaping up? CDER has approved 30 novel drugs so far, half of which are oral solid dose formulations.
Open in Who Shared Issue with article?

What cell and gene therapy CDMOs want sponsors to know

|
By Karen Langhauser Verified
| Cell & Gene Therapy Review Verified
In the cell and gene therapy space, the road from promising biological concept to commercialized treatment is long and complex. No matter how elegant the science, scale-up and manufacturing is often a key determinant of a therapy’s safety, efficacy and commercial viability — making CDMOs structurally vital to the industry. Bringing next-generation therapies to patients at industrial scale requires close collaboration between sponsors and their partners.
Open in Who Shared Issue with article?
See all 186 articles